Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Belatacept.

Literature DB >> 21878974

Belatacept.

Flavio Vincenti, Argyris Dritselis, Peter Kirkpatrick.

Abstract

Mesh：

Substances：

Year: 2011 PMID： 21878974 DOI： 10.1038/nrd3536

Source DB: PubMed Journal: Nat Rev Drug Discov ISSN： 1474-1776 Impact factor: 84.694

× No keyword cloud information.

7 in total

1. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties.

Authors: Christian P Larsen; Thomas C Pearson; Andrew B Adams; Paul Tso; Nozomu Shirasugi; Elizabeth Strobert; Dan Anderson; Shannon Cowan; Karen Price; Joseph Naemura; John Emswiler; JoAnne Greene; Lori Ann Turk; Jurgen Bajorath; Robert Townsend; David Hagerty; Peter S Linsley; Robert J Peach
Journal: Am J Transplant Date: 2005-03 Impact factor: 8.086

2. Long-term renal allograft survival in the United States: a critical reappraisal.

Authors: K E Lamb; S Lodhi; H-U Meier-Kriesche
Journal: Am J Transplant Date: 2010-10-25 Impact factor: 8.086

Review 3. Novel strategies in immunosuppression: issues in perspective.

Authors: Allison Webber; Ryutaro Hirose; Flavio Vincenti
Journal: Transplantation Date: 2011-05-27 Impact factor: 4.939

4. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure.

Authors: Robert S Gaston; J Michael Cecka; Bert L Kasiske; Ann M Fieberg; Robert Leduc; Fernando C Cosio; Sita Gourishankar; Joseph Grande; Philip Halloran; Lawrence Hunsicker; Roslyn Mannon; David Rush; Arthur J Matas
Journal: Transplantation Date: 2010-07-15 Impact factor: 4.939

5. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study).

Authors: A Durrbach; J M Pestana; T Pearson; F Vincenti; V D Garcia; J Campistol; M del Carmen Rial; S Florman; A Block; G Di Russo; J Xing; P Garg; J Grinyó
Journal: Am J Transplant Date: 2010-03 Impact factor: 8.086

6. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).

Authors: F Vincenti; B Charpentier; Y Vanrenterghem; L Rostaing; B Bresnahan; P Darji; P Massari; G A Mondragon-Ramirez; M Agarwal; G Di Russo; C-S Lin; P Garg; C P Larsen
Journal: Am J Transplant Date: 2010-03 Impact factor: 8.086

7. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule.

Authors: P S Linsley; P M Wallace; J Johnson; M G Gibson; J L Greene; J A Ledbetter; C Singh; M A Tepper
Journal: Science Date: 1992-08-07 Impact factor: 47.728

7 in total

13 in total

1. Structure and cancer immunotherapy of the B7 family member B7x.

Authors: Hyungjun Jeon; Vladimir Vigdorovich; Sarah C Garrett-Thomson; Murali Janakiram; Udupi A Ramagopal; Yael M Abadi; Jun Sik Lee; Lisa Scandiuzzi; Kim C Ohaegbulam; Jordan M Chinai; Ruihua Zhao; Yu Yao; Ying Mao; Joseph A Sparano; Steven C Almo; Xingxing Zang
Journal: Cell Rep Date: 2014-10-30 Impact factor: 9.423

2. HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function.

Authors: Ruihua Zhao; Jordan M Chinai; Susan Buhl; Lisa Scandiuzzi; Anjana Ray; Hyungjun Jeon; Kim C Ohaegbulam; Kaya Ghosh; Aimin Zhao; Matthew D Scharff; Xingxing Zang
Journal: Proc Natl Acad Sci U S A Date: 2013-05-28 Impact factor: 11.205

Review 3. Transplantation tolerance: from theory to clinic.

Authors: Ephraim J Fuchs
Journal: Immunol Rev Date: 2014-03 Impact factor: 12.988

Review 4. Co-opting biology to deliver drugs.

Authors: Parisa Yousefpour; Ashutosh Chilkoti
Journal: Biotechnol Bioeng Date: 2014-07-21 Impact factor: 4.530

Belatacept.

1. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties.

2. Long-term renal allograft survival in the United States: a critical reappraisal.

Review 3. Novel strategies in immunosuppression: issues in perspective.

4. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure.

5. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study).

6. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).

7. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule.

1. Structure and cancer immunotherapy of the B7 family member B7x.

2. HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function.

Review 3. Transplantation tolerance: from theory to clinic.

Review 4. Co-opting biology to deliver drugs.

5. The nature of activatory and tolerogenic dendritic cell-derived signal II.

6. Lipids, blood pressure, kidney - what was new in 2011?

7. How to kill two birds with one transgenic pig.

8. Combining Theoretical and Experimental Techniques to Study Murine Heart Transplant Rejection.

9. The role of coinhibitory signaling pathways in transplantation and tolerance.

10. Cryptic association of B7-2 molecules and its implication for clustering.